Ovid Therapeutics Inc. – Filings and Transcripts

NASDAQ: OVID
Share price (4/8/26): $2.60
Market cap (4/8/26): $343 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

ended 03/31/25 Q1

ended 12/31/24 FY 2024 – amended

Prospectuses and Registrations Filter

Registration of securities for employees

Prospectus supplement

Shelf registration

Registration of securities for employees

Prospectus supplement for primary offering

Ownership Filter

Fitzgerald Kevin Joseph

Papadopoulos Stelios

Alexander Margaret A.

News Filter

Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous

Shareholder Vote Results

Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

Announces Positive Topline Results for the Next-Generation GABA- Aminotransferase Inhibitor, OV329, That Demonstrate Strong Inhibitory Activity and a Potential Best-In-Category Safety Profile

Proxies Filter

Definitive proxy

Preliminary proxy

Preliminary proxy related to merger

Additional info about upcoming vote

Definitive proxy

Other Filter

Notice of effectiveness

Scanned paper annual report submission

Scanned paper annual report submission

Notice of effectiveness

Correspondence with the SEC